APA (7th ed.) Citation

Zhou, Y., Zhang, J., Wang, W., Bao, L., Fang, B., Gao, D., . . . Yang, G. (2025). Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial. Cancer medicine (Malden, MA), 14(8), e70890-n/a. https://doi.org/10.1002/cam4.70890

Chicago Style (17th ed.) Citation

Zhou, Ya‐Lan, Jin‐Qiao Zhang, Wei Wang, Li Bao, Bai‐Jun Fang, Da Gao, Li‐Ping Su, Wen‐Ming Chen, and Guang‐Zhong Yang. "Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial." Cancer Medicine (Malden, MA) 14, no. 8 (2025): e70890-n/a. https://doi.org/10.1002/cam4.70890.

MLA (9th ed.) Citation

Zhou, Ya‐Lan, et al. "Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial." Cancer Medicine (Malden, MA), vol. 14, no. 8, 2025, pp. e70890-n/a, https://doi.org/10.1002/cam4.70890.